×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Skip to main content
Tags: astrazeneca | shot | covid | omicron

AstraZeneca COVID Drug Neutralizes Omicron Subvariants in Study

AstraZeneca COVID Drug Neutralizes Omicron Subvariants in Study
(AP)

Monday, 21 March 2022 03:41 AM EDT

AstraZeneca said its antibody-based cocktail to prevent and treat COVID-19 was shown to retain neutralizing activity against Omicron coronavirus variants, including the highly contagiouos BA.2 subvariant, in an independent lab study.

Data from the study by the Washington University showed the therapy reduced the amount of virus detected in samples of all tested omicron subvariants in mice lungs, the London-listed drugmaker said Monday. The study has yet to be peer reviewed.

The therapy, Evusheld, was tested against the BA.1, BA.1.1, and BA.2 subvariants of Omicron and it was also shown to limit inflammation in the lungs.

"The findings further support Evusheld as a potential important option to help protect vulnerable patients such as the immunocompromised who could face poor outcomes if they were to become infected with COVID-19," senior AstraZeneca executive John Perez said.

The World Health Organization said last week figures showing a global rise in COVID-19 cases could herald a much bigger problem, as the omicron and BA.2 variants spread amid the easing of restrictions and testing.

Vaccines rely on an intact immune system to develop targeted antibodies and infection-fighting cells, but Evusheld contains lab-made antibodies designed to linger in the body for months to contain the virus in case of an infection.

The results come after Britain last week approved the therapy for preventing infections in adults with poor immune response. Evusheld is currently under a European review and has been authorized in the United States.

© 2022 Thomson/Reuters. All rights reserved.


Newsfront
AstraZeneca said its antibody-based cocktail to prevent and treat COVID-19 was shown to retain neutralizing activity against Omicron coronavirus variants, including the highly contagiouos BA.2 subvariant, in an independent lab study.
astrazeneca, shot, covid, omicron
239
2022-41-21
Monday, 21 March 2022 03:41 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved
Download the NewsmaxTV App
NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved